Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65](S0302283816002724)(10.1016/j.eururo.2016.03.015)

We wish to report two typographical errors that recently came to our attention in this article. (1) The correct affiliation for Dr. R. Jeffrey Karnes is “^a Department of Urology, Mayo Clinic, Rochester, MN, USA” rather than “^d Health Research and Educational Trust, Chicago, IL, USA”.(2) In the first paragraph of the Discussion, the text “a concurrent 22% decrease” should be “a concurrent 10% decrease.” Similarly, in paragraph 5, the text “an absolute 22% reduction” should be “an absolute 10% reduction.” The remainder of the article correctly specifies the “10%” reduction in 30-d complication rates, and the findings and conclusions remain unaltered.Conflicts of interest: The authors have nothing to disclose.